These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1032 related articles for article (PubMed ID: 35288347)
1. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347 [TBL] [Abstract][Full Text] [Related]
2. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy. Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. Yamshon S; Gribbin C; Chen Z; Demetres M; Pasciolla M; Alhomoud M; Martin P; Shore T Transplant Cell Ther; 2024 Jan; 30(1):73.e1-73.e12. PubMed ID: 37279856 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy. Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928 [TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338 [TBL] [Abstract][Full Text] [Related]
8. The influence of CRS and ICANS on the efficacy of anti-CD19 CAR-T treatment for B-cell acute lymphoblastic leukemia. Ma Y; Zhou H; Zhang J; Zhang Q; Li Y; Xie R; Zhang B; Shen Z; Li P; Liang A; Zhou K; Han L; Hu Y; Xu K; Sang W; Wang X Front Immunol; 2024; 15():1448709. PubMed ID: 39399502 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment. Gu T; Hu K; Si X; Hu Y; Huang H WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757 [TBL] [Abstract][Full Text] [Related]
10. EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome. Hernani R; Aiko M; Victorio R; Benzaquén A; Pérez A; Piñana JL; Hernández-Boluda JC; Amat P; Pastor-Galán I; Remigia MJ; Ferrer-Lores B; Micó M; Carbonell N; Ferreres J; Blasco-Cortés ML; Santonja JM; Dosdá R; Estellés R; Campos S; Martínez-Ciarpaglini C; Ferrández-Izquierdo A; Goterris R; Gómez M; Teruel A; Saus A; Ortiz A; Morello D; Martí E; Carretero C; Calabuig M; Tormo M; Terol MJ; Cases P; Solano C Clin Neurophysiol; 2024 Jul; 163():132-142. PubMed ID: 38733703 [TBL] [Abstract][Full Text] [Related]
11. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy. Ruff MW; Siegler EL; Kenderian SS Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients. Sharma A; Singh V; Deol A Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048 [TBL] [Abstract][Full Text] [Related]